論文 - 詳細
| RRC ID | 43960 |
|---|---|
| 著者 | Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. |
| タイトル | Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. |
| ジャーナル | Clin Cancer Res |
| Abstract |
PURPOSE:Hepatocellular carcinoma (HCC) is a heterogeneous cancer with active Wnt signaling. Underlying biologic mechanisms remain unclear and no drug targeting this pathway has been approved to date. We aimed to characterize Wnt-pathway aberrations in HCC patients, and to investigate sorafenib as a potential Wnt modulator in experimental models of liver cancer. EXPERIMENTAL DESIGN:The Wnt-pathway was assessed using mRNA (642 HCCs and 21 liver cancer cell lines) and miRNA expression data (89 HCCs), immunohistochemistry (108 HCCs), and CTNNB1-mutation data (91 HCCs). Effects of sorafenib on Wnt signaling were evaluated in four liver cancer cell lines with active Wnt signaling and a tumor xenograft model. RESULTS:Evidence for Wnt activation was observed for 315 (49.1%) cases, and was further classified as CTNNB1 class (138 cases [21.5%]) or Wnt-TGFβ class (177 cases [27.6%]). CTNNB1 class was characterized by upregulation of liver-specific Wnt-targets, nuclear β-catenin and glutamine-synthetase immunostaining, and enrichment of CTNNB1-mutation-signature, whereas Wnt-TGFβ class was characterized by dysregulation of classical Wnt-targets and the absence of nuclear β-catenin. Sorafenib decreased Wnt signaling and β-catenin protein in HepG2 (CTNNB1 class), SNU387 (Wnt-TGFβ class), SNU398 (CTNNB1-mutation), and Huh7 (lithium-chloride-pathway activation) cell lines. In addition, sorafenib attenuated expression of liver-related Wnt-targets GLUL, LGR5, and TBX3. The suppressive effect on CTNNB1 class-specific Wnt-pathway activation was validated in vivo using HepG2 xenografts in nude mice, accompanied by decreased tumor volume and increased survival of treated animals. CONCLUSIONS:Distinct dysregulation of Wnt-pathway constituents characterize two different Wnt-related molecular classes (CTNNB1 and Wnt-TGFβ), accounting for half of all HCC patients. Sorafenib modulates β-catenin/Wnt signaling in experimental models that harbor the CTNNB1 class signature. |
| 巻・号 | 18(18) |
| ページ | 4997-5007 |
| 公開日 | 2012-9-15 |
| DOI | 10.1158/1078-0432.CCR-11-2322 |
| PII | 1078-0432.CCR-11-2322 |
| PMID | 22811581 |
| PMC | PMC3446854 |
| MeSH | Animals Antineoplastic Agents / pharmacology* Biomarkers, Tumor / genetics Biomarkers, Tumor / metabolism Carcinoma, Hepatocellular / genetics Carcinoma, Hepatocellular / metabolism* Cell Line, Tumor Cluster Analysis Female Gene Expression Profiling Genomics Hep G2 Cells Humans Liver Neoplasms / genetics Liver Neoplasms / metabolism* Mice Niacinamide / analogs & derivatives* Niacinamide / pharmacology Phenylurea Compounds / pharmacology* Protein Kinase Inhibitors / pharmacology* Reproducibility of Results Sorafenib Transforming Growth Factor beta / genetics Transforming Growth Factor beta / metabolism Wnt Proteins / metabolism* Wnt Signaling Pathway / drug effects* beta Catenin / genetics beta Catenin / metabolism |
| IF | 10.107 |
| 引用数 | 148 |
| WOS 分野 | ONCOLOGY |
| リソース情報 | |
| ヒト・動物細胞 | HuH-7 |